Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment
Atzori, Laura
First
Writing - Review & Editing
;Bonato, FilippoSecond
Writing - Original Draft Preparation
;Pilloni, LucaPenultimate
Member of the Collaboration Group
;Rongioletti, FrancoLast
Supervision
2020-01-01
Abstract
Mental retardation is a potential limitation to self-administration of innovative biologic treatment, which is otherwise very effective for devastating chronic inflammatory conditions, such as hidradenitis suppurativa (HS). We report our successful experience with a 34-year-old woman, who was genetically affected by Warkany syndrome, which causes intellectual disability. This patient was unable to maintain long-term antibiotic regimen and was disappointed by the limited results in her 12 years' history of painful draining fistulae and abscesses; however, she enthusiastically adhered to adalimumab 40 mg/once weekly treatment. After 52 weeks, treatment compliance is excellent, the patient is satisfied with the HS improvements, and no adverse effects have been reported.File | Size | Format | |
---|---|---|---|
Warkany e HS Atzori_et_al-2019-Dermatologic_Therapy.pdf Solo gestori archivio
Type: versione post-print
Size 667.33 kB
Format Adobe PDF
|
667.33 kB | Adobe PDF | & nbsp; View / Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.